XBI241227C98500
- 0.05
- 0.000.00%
SPDR S&P Biotech ETF Newsroom
Bulls Vs. Bears: Is the Schwab U.S. Dividend Equity ETF a Good Investment?
17 Analysts Assess Biogen: What You Need To Know
Biogen Analyst Ratings
After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.
The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.
Analyst Expectations For Amgen's Future
Amgen Analyst Ratings
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
How Is The Market Feeling About United Therapeutics?
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Global enterprises are "fully powered" to borrow money! The scale will reach 8 trillion dollars in 2024, setting a record.
Bankers stated that low financing costs were the initial reason for companies to choose to issue Bonds early, as they wanted to avoid the market volatility risks that could arise around the USA elections. However, after Trump's election victory, the market's credit spreads further narrowed, prompting some companies to decide to lock in their borrowing needs for the following year in order to secure funds under favorable market conditions.
Year-end review of the US stock market: The seven giants continue to surge, and investors prepare for Trump 2.0.
In 2024, the US stock market is driven by the AI boom, the Federal Reserve's interest rate cuts, and strong economic growth, with the three major indices reaching new highs: the S&P 500 Index up 25% for the year, the Nasdaq Composite Index up 31% for the year, and the Dow Jones up 14% for the year; following Trump's return, a series of policies are expected to create huge waves, and the Federal Reserve's comments indicating a slowdown in interest rate cuts have already disturbed the market.
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Looking At Amgen's Recent Unusual Options Activity
Medical stocks welcome a rebound opportunity: three major star companies may become investment highlights in 2025.
In 2024, the performance of the Medical Industry is disappointing for investors, but 2025 may bring a glimmer of hope.
Top Dividend Picks for 2025 According to Seeking Alpha's Quant Metrics
10 Health Care Stocks With Whale Alerts In Today's Session